Botanical/Drug Interactions in HIV: Glucuronidation
This study has been completed.
Sponsor:
Information provided by:
National Center for Complementary and Alternative Medicine (NCCAM)
ClinicalTrials.gov Identifier:
NCT00065741
First received: July 31, 2003
Last updated: March 21, 2007
Last verified: March 2007
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
A series of clinical studies will be conducted in normal, healthy adult volunteers to evaluate the potential for alterations in the pharmacokinetics of anti HIV drugs when botanicals/nutriceuticals are given concurrently via the oral route. Both the drugs and botanicals are known to rely upon or to modulate, respectively, metabolism via glucuronidation.
| Condition | Intervention | Phase |
|---|---|---|
|
HIV Seronegativity |
Drug: silymarin |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Pharmacokinetics Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | Botanical/Drug Interactions in HIV: Glucuronidation |
Resource links provided by NLM:
Further study details as provided by National Center for Complementary and Alternative Medicine (NCCAM):
Eligibility| Ages Eligible for Study: | 18 Years to 50 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion criteria:
Absence of HIV-1 infections
- Body mass index less than or equal to 30 kg/m2 and weigh at least 50 kg.
- Laboratory values obtained within 7 days of study entry within normal range for healthy volunteers.
- Able to be compliant with dosing schedules and diary record keeping.
- Able to follow dietary restrictions associated with the protocol.
- Ability and willingness to provide informed consent
- All women of reproductive potential must have a negative pregnancy test
- All women of reproductive potential to use contraception methods as defined by protocol
- All study subjects (male and female) must agree to not participate in a conception process
Exclusion Criteria:
- History of any acute or chronic illness that requires current medical therapy including active gastrointestinal conditions that might interfere with drug absorption.
- History of hepatic, renal, cardiovascular, gastrointestinal diseases.
- Current gastrointestinal disturbance.
- Receipt of any prescribed or over the counter medication or ingested CAM during the 30 days prior to study entry except: Over the counter acetaminophen or ibuprofen at doses not exceeding package labeling guidelines.
- Any medical condition that, in the opinion of the investigator, would interfere with the subject’s ability to participate in this protocol.
- Pregnancy or breastfeeding.
- Allergy/sensitivity to study agent(s) or their formulations.
- Active drug or alcohol abuse or dependence, which in the opinion of the investigator would interfere with adherence to study requirements or would endanger the subject’s health while on study.
- Before entering the study, subjects must agree not to consume alcohol for 48 hours prior to PK sampling days.
- Participation in any investigational drug studies within 30 days prior to study entry and during study.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00065741
Locations
| United States, North Carolina | |
| General Clinical Research Center, Univiversity Of North Carolina at Chapel Hill | |
| Chapel Hill, North Carolina, United States, 27599 | |
Sponsors and Collaborators
Investigators
| Principal Investigator: | Philip C Smith, PhD | School of Pharmacy, UNC Chapel Hill |
| Study Director: | David A Wohl, MD | Department of Medicine, AIDS Clinical Trials Unit, University of North Carolina at Chapel Hill |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00065741 History of Changes |
| Other Study ID Numbers: | R21 AT001376-01A1 |
| Study First Received: | July 31, 2003 |
| Last Updated: | March 21, 2007 |
| Health Authority: | United States: Federal Government |
Keywords provided by National Center for Complementary and Alternative Medicine (NCCAM):
|
Milk thistle silymarin piperine glucarate zidovudine abacavir mycophenolate mofetil |
HIV pharmacokinetics interaction glucuronidation Healthy Complementary Therapies |
Additional relevant MeSH terms:
|
Silymarin Antioxidants Molecular Mechanisms of Pharmacological Action |
Pharmacologic Actions Protective Agents Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on June 18, 2013